At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,134 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-marketing Surveillance to Assess the Safety and Effectiveness of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the "Standard for Re-examination of New Drugs"
In Brief
An observational study for Hepatitis C. Completed, enrolled 3,134 participants across 61 sites.
Detailed Summary
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Maviret (Glecaprevir/Pibrentasvir) administered under a normal, routine treatment practice by Korean patients with Chronic Hepatitis C Genotypes 1 to 6
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
First PostedNov 2018
Primary CompletionJul 2023
TodayJul 2026
First PostedNov 14, 2018
Enrollment StartSep 26, 2018
Primary CompletionJul 21, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.6 years ago